Publications by authors named "Frederic Viret"

Claim this Profile
N
Nivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.
Olivier Trédan, Delphine Loirat, Sylvie Chabaud, Philippe Toussaint, Thierry Petit, Frédéric Viret

Breast· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
Arthur Géraud, Paul Gougis, Alexandre de Nonneville, Mathilde Beaufils, François Bertucci, Frederic Viret

Cancer Treat Rev· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
Alexandre Giraudo, Renaud Sabatier, Frederique Rousseau, Alexandre De Nonneville, Anthony Gonçalves, Frederic Viret

Cancers (Basel)· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy for breast cancer: Pathologic response rates but not tumor size, has an independent prognostic impact on survival.
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Laura Sabiani, Max Buttarelli, Frédéric Viret

Cancer Med· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial.
Fernanda Mosele, Elise Deluche, Amelie Lusque, Loïc Le Bescond, Thomas Filleron, Frederic Viret

Nat Med· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of aromatase inhibitor-induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer.
Bénédicte Mugnier, Anthony Goncalves, Aurélie Daumas, Anne-Laure Couderc, Essia Mezni, Frédéric Viret

Osteoporos Int· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers.
Alexandre de Nonneville, Gilles Houvenaeghel, Monique Cohen, Laura Sabiani, Marie Bannier, Frederic Viret

Eur J Cancer· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study.
Gilles Houvenaeghel, Alexandre de Nonneville, Monique Cohen, Frédéric Viret, Sandrine Rua

J Surg Res (Houst)· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer.
Renaud Sabatier, Johan Martin, Cécile Vicier, Mathilde Guérin, Audrey Monneur, Frédéric Viret

J Clin Med· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.
Simon Launay, Renaud Sabatier, Serge Brunelle, Benjamin Esterni, Carole Tarpin, Frederic Viret

Anticancer Res· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial.
Christophe Tournigand, Benoist Chibaudel, Benoit Samson, Werner Scheithauer, Dewi Vernerey, Frédéric Viret

Lancet Oncol· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

Ann Oncol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation plus docetaxel and cisplatin in locally advanced pancreatic carcinoma: a non-comparative randomized phase II trial.
Michel Ducreux, Marc Giovannini, Charlotte Baey, Carmen Llacer, Jaafar Bennouna, Frédéric Viret

Dig Liver Dis· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Contributing to research via biobanks: what it means to cancer patients.
Isabelle Pellegrini, Christian Chabannon, Julien Mancini, Frederic Viret, Norbert Vey

Health Expect· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
David Malka, Pascale Cervera, Stéphanie Foulon, Tanja Trarbach, Christelle de la Fouchardière, Frédéric Viret

Lancet Oncol· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Initial experience with hyperthermic intraperitoneal chemotherapy.
Olivier Turrini, Eric Lambaudie, Marion Faucher, Frédéric Viret, Jean Louis Blache

Arch Surg· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study.
Eric Van Cutsem, Sabine Tejpar, Dirk Vanbeckevoort, Marc Peeters, Yves Humblet, Frederic Viret

J Clin Oncol· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cetuximab plus FOLFIRINOX (ERBIRINOX) as first-line treatment for unresectable metastatic colorectal cancer: a phase II trial.
Eric Assenat, Francoise Desseigne, Simon Thezenas, Frédéric Viret, Laurent Mineur

Oncologist· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Docetaxel- and 5-FU-concurrent radiotherapy in patients presenting unresectable locally advanced pancreatic cancer: a FNCLCC-ACCORD/0201 randomized phase II trial's pre-planned analysis and case report of a 5.5-year disease-free survival.
Lucie Oberic, Frédéric Viret, Charlotte Baey, Marc Ychou, Jaafar Bennouna

Radiat Oncol· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors of tumor response after neoadjuvant chemoradiation for locally advanced rectal cancer.
Laurence Moureau-Zabotto, Bertrand Farnault, Cecile de Chaisemartin, Benjamin Esterni, Bernard Lelong, Frederic Viret

Int J Radiat Oncol Biol Phys· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genome profiling of pancreatic adenocarcinoma.
David J Birnbaum, José Adélaïde, Emilie Mamessier, Pascal Finetti, Arnaud Lagarde, Frédéric Viret

Genes Chromosomes Cancer· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pancreatic head resectable adenocarcinoma: preoperative chemoradiation improves local control but does not affect survival.
Louise Barbier, Olivier Turrini, Emilie Grégoire, Frédéric Viret, Yves-Patrice Le Treut

HPB (Oxford)· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Consent for biobanking: assessing the understanding and views of cancer patients.
Julien Mancini, Isabelle Pellegrini, Frédéric Viret, Norbert Vey, Lise-Marie Daufresne

J Natl Cancer Inst· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preservation of replaced or accessory right hepatic artery during pancreaticoduodenectomy for adenocarcinoma: impact on margin status and survival.
Olivıer Turrini, Eric A Wiebke, Jean Robert Delpero, Frédéric Viret, Keith D Lillemoe

J Gastrointest Surg· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience.
Olivier Turrini, Frédéric Viret, Laurence Moureau-Zabotto, Jérome Guiramand, Vincent Moutardier

Oncology· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis